Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502884 | 1.00 | MGLL (0.35) | MGLLLMNAGAAMAPTKMT2A | |
| SCHEMBL4498568 | 1.00 | MGLL (0.35) | MGLLLMNAGAAMAPTKMT2A | |
| SCHEMBL4489137 | 0.89 | KMT2A (0.35) | KMT2AMEN1POLB | |
| SCHEMBL4490091 | 0.89 | KMT2A (0.35) | KMT2AMEN1POLB | |
| SCHEMBL4489220 | 0.89 | KMT2A (0.35) | KMT2AMEN1POLB | |
| SCHEMBL4496497 | 0.88 | ALDH1A1 (0.34) | MGLLLMNAGAAMAPTKMT2A | |
| SCHEMBL4490943 | 0.87 | ALDH1A1 (0.46) | LMNAKMT2AMEN1 | |
| SCHEMBL4489743 | 0.86 | KMT2A (0.39) | MGLLKMT2ASLC2A1SLC2A4 | |
| SCHEMBL4502357 | 0.86 | KMT2A (0.39) | MGLLKMT2ASLC2A1SLC2A4 | |
| SCHEMBL4495844 | 0.86 | KMT2A (0.39) | MGLLKMT2ASLC2A1SLC2A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563793-B2 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2009-07-21 | — | — | US | claimed |
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2006-07-20 | — | — | US | claimed |
| US-7563793-B2 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160815-A1 | Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents | ESR1, GPER1, ESR2 | MGLL 4656/4885LMNA 3776/4885GAA 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.